CMS Targets $246B in Medicaid Cuts as UnitedHealth Eases Prior Authorization

CMS Moves to Cut $246B From Federal Medicaid Spending

A CMS proposed rule (CMS-2452-P) would restrict how states structure Medicaid provider taxes, cutting federal Medicaid spending by an estimated $246 billion over 10 years. Providers would save $163.7 billion in taxes but see Medicaid payments fall $220.3 billion over the same period, a net loss for hospitals and safety-net providers. Comments are due September 21, 2026, ahead of an October 1, 2026 effective date.

Eli Lilly's 13th Deal of 2026 Bets on Autoimmune Disease

Eli Lilly agreed to acquire Merida Biosciences for up to $2.875 billion in cash, gaining MER511 (thyroid eye disease/Graves' disease) and MER769 (allergic conditions like asthma), biologics designed to selectively degrade pathogenic autoantibodies without broadly suppressing the immune system. It is Lilly's 13th acquisition of the year, funded by blockbuster GLP-1 cash flow.

UnitedHealthcare Scraps Prior Authorization for 30% of Services

UnitedHealthcare will lift prior-authorization requirements on roughly 1,700 diagnostic codes, covering about 30% of services, effective October 1, 2026, a move that could ease provider administrative burden and support UNH's payer relationships. The announcement lifted UNH shares alongside reiterated FY2026 adjusted EPS guidance of $19.50-$20.00.

Biotech Dealmakers and Payers Easing Friction

• Eli Lilly's $2.875 billion acquisition of Merida Biosciences extends its 2026 dealmaking streak to 13 transactions, adding a differentiated autoantibody-degradation platform in autoimmune and allergic disease.
• UnitedHealthcare's rollback of prior authorization for roughly 1,700 diagnostic codes (about 30% of services) lifted UNH shares and reinforces the company's push to reduce administrative friction with providers ahead of the October 1, 2026 effective date.
• CMS reported 600,000 seniors have enrolled in the new Medicare GLP-1 access program in its first two months, a tailwind for LLY's Zepbound and the broader obesity-drug category.

Hospitals and Safety-Net Providers Facing a Medicaid Funding Cut

• CMS's Medicaid provider tax proposed rule would cut federal Medicaid spending by $246 billion over 10 years, leaving providers a net $220.3 billion worse off even after accounting for tax savings.
• HCA Healthcare continues to digest its July 2026 guidance cut, driven by a $400 million second-quarter EBITDA hit from ACA exchange coverage losses; shares traded near $410 this week, well below the 52-week high of $556.52.
• Labor tension at HCA persists, with workers publicly pushing for higher pay and staffing amid the company's reported multibillion-dollar profits.

Large-Cap Pharma and Biotech Digest a Cooling Rally

• MRK closed near its 52-week high at $151.64 (+1.19%) while MRNA fell 2.24% to $150.81 as the market absorbed a $2.6 billion Moderna convertible-note offering alongside continued scrutiny of the mRNA-oncology data.
• Intuitive Surgical rose 0.71% to $371.88 but remains well below its 52-week high of $603.88, reflecting lingering concern over ACA/Medicaid coverage effects on procedure volumes even as analysts see meaningful upside.
• CVS Health slipped modestly to $97.22 despite a Strong Buy analyst consensus and a top large-cap pick rating from Jefferies, underscoring a market still parsing 340B and reimbursement headwinds against strong operating execution.

Trading near its 52-week high as healthcare's 2026 defensive/re-rating rotation continues, supported by State Street's Q3 2026 upgrade of the sector to positive.

Sitting near its 52-week high and approaching its 2021 level of $174.79, reflecting the ongoing 2026 biotech re-rating and continued M&A momentum led by the Lilly/Merida deal.

UNH sits roughly seven-tenths of the way through its wide 52-week range, supported this week by the prior-authorization rollback and reiterated FY2026 guidance.

XLV and XBI hold near current highs as biotech M&A sentiment stays constructive following the Lilly/Merida deal, while MRK/MRNA continue to consolidate rather than extend last month's rally. Hospital and payer names trade on incremental commentary about the Medicaid provider tax rule's comment period and any further prior-authorization announcements from other national insurers, rather than a single dominant story. No FDA PDUFA date or CMS final rule falls within this specific window.

Additional national payers follow UnitedHealthcare's lead on prior-authorization simplification, easing provider sentiment; further biotech M&A is announced, pushing XBI toward fresh multi-year highs; MRK and MRNA stabilize and resume upward momentum as investors conclude recent pullbacks were technical; early signals suggest the Medicaid provider tax rule may be softened following stakeholder feedback.

Early feedback on the Medicaid provider tax rule signals it will be finalized largely as proposed, compounding HCA's existing payer-mix pressure and spreading concern to other hospital operators; MRNA's convertible-note dilution combines with broader profit-taking to deepen its pullback; ISRG's coverage-erosion concerns gain further traction amid weak procedure-volume commentary.

CMS is tightening Medicaid financing for hospitals at the same moment a dominant national payer is loosening administrative friction, a bifurcated regulatory environment where providers absorb coverage-related losses while payers and disciplined biotech dealmakers hold the stronger hand heading into Q4 2026.

What we know with high confidence

• ✓CMS's Medicaid provider tax proposed rule (CMS-2452-P) targets a $246 billion reduction in federal Medicaid spending over 10 years, with comments due September 21, 2026. [CMS; Holland & Knight; Becker's Payer Issues]
• ✓Providers are projected to see a net $220.3 billion reduction in Medicaid payments over 10 years under the rule, despite $163.7 billion in provider tax savings over the same period. [HFMA]
• ✓Eli Lilly agreed to acquire Merida Biosciences for up to $2.875 billion in cash, its 13th acquisition of 2026, to obtain MER511 and MER769 for autoimmune and allergic disease. [Reuters; WSJ; PR Newswire]
• ✓UnitedHealthcare will lift prior-authorization requirements on approximately 1,700 diagnostic codes covering about 30% of services, effective October 1, 2026. [Reuters; Forbes]
• ✓HCA Healthcare's Q2 2026 results included a $400 million EBITDA hit from ACA exchange coverage losses, driving a cut to full-year 2026 EPS guidance to $28.70-$30.50 from $29.10-$31.50. [Healthcare Dive; TipRanks]

What could break the thesis

• !CMS could finalize the Medicaid provider tax rule largely as proposed following the September 21, 2026 comment period, compounding payer-mix pressure already visible at HCA Healthcare.
• !The full list of manufacturers in the Trump administration's new drug-pricing deals could expand pressure on large-cap pharma margins beyond the initial announced cohort.
• !Moderna's $2.6 billion convertible-note dilution could weigh on MRNA shares even as the underlying mRNA-oncology data remains a long-term platform validator.
• !Intuitive Surgical's coverage-erosion thesis could gain further traction if Q3 2026 procedure-volume data shows measurable ACA/Medicaid-related softness.

FDA Status

No major new FDA approvals were confirmed this week. The FDA's September 2026 PDUFA calendar includes three notable target action dates: levacetylleucine for ataxia-telangiectasia (September 19), zilurgisertib for fibrodysplasia ossificans progressiva in patients 12 and older (September 26), and a pediatric expansion of mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy (September 30).

CMS Status

CMS's proposed rule (CMS-2452-P), published July 21, 2026, would restrict state Medicaid provider tax structures under section 71115 of the 2025 reconciliation law, with an estimated $246 billion reduction in federal Medicaid spending over 10 years; the comment period closes September 21, 2026, ahead of an October 1, 2026 effective date for the underlying statutory threshold change. Separately, CMS confirmed 600,000 Medicare beneficiaries have enrolled in the new GLP-1 weight-loss drug access program launched earlier in 2026.

Legislative Status

No major new federal healthcare legislation was enacted this week. The Medicaid provider tax rule implements section 71115 of the 2025 reconciliation law ('One Big Beautiful Bill Act'), while the Trump administration's newly confirmed round of voluntary drug-pricing deals with roughly a dozen manufacturers extends an existing executive-branch drug-pricing initiative rather than new statutory action.